WO1998017266A2 - Preparation pharmaceutique contenant un derive d'amidine et de la procaine - Google Patents
Preparation pharmaceutique contenant un derive d'amidine et de la procaine Download PDFInfo
- Publication number
- WO1998017266A2 WO1998017266A2 PCT/EP1997/005724 EP9705724W WO9817266A2 WO 1998017266 A2 WO1998017266 A2 WO 1998017266A2 EP 9705724 W EP9705724 W EP 9705724W WO 9817266 A2 WO9817266 A2 WO 9817266A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- preparation
- preparation according
- pharmaceutical
- trypanosomiasis
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 14
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 201000002311 trypanosomiasis Diseases 0.000 claims abstract description 7
- 229960004919 procaine Drugs 0.000 claims abstract description 5
- 150000001409 amidines Chemical class 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 4
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 3
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 claims description 3
- 229950007095 diminazene Drugs 0.000 claims description 3
- 229960004448 pentamidine Drugs 0.000 claims description 3
- 229960005222 phenazone Drugs 0.000 claims description 3
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229950010741 aceturate Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
Definitions
- the invention relates to a pharmaceutical preparation for trypanosomiasis prophylaxis.
- Arsenic preparations and trypan dyes were used for chemotherapy, but they have harmful side effects.
- a preparation for trypanosomiasis prophylaxis which contains at least one active substance against protozoa from the group of the amidines, preferably diminazene di-aceturate (4,4'-diamidino-diazoaminobenzenediacetamidoacetate) and / or pentamidine ( 4,4 '- (Pentamethylenedioxy) -dibenzamidin), as well as procaine or a procaine derivative.
- the preparation also contains phenazone, which has an antipyretic effect in the case of an existing infection.
- the preparation is preferably used as an injection solution, so that the individual substances first in solution have to be brought.
- a mixture of cellulose ether, in particular methyl cellulose, glycerol and water, is advantageously mixed with the solids, a clear solution being able to be prepared simply by stirring.
- Procaine or procaine derivative e.g. hydrochloride
- Emulsifier-water mixture glycerin
- Water suitable for pharmaceutical purposes, e.g. physiologically balanced water
- the preparation according to the invention enables trypanomiasis prophylaxis and advantageously the preparation is also simultaneously suitable for chemotherapy of an existing protozoan infection.
- the preparation is particularly intended for the veterenary area. However, it is also in human medicine can be used so that, particularly advantageous for vacationers, a kind of vaccination can be carried out.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention vise à mettre au point une préparation pharmaceutique permettant d'assurer la prophylaxie de trypanosomiase. A cet effet, il est prévu une préparation pharmaceutique se caractérisant en ce qu'elle contient au moins un composé du groupe comprenant les amidines et la procaïne ou un dérivé de procaïne, ledit composé étant actif à l'encontre de protozoaires.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97912195A EP0936907A2 (fr) | 1996-10-18 | 1997-10-17 | Preparation pharmaceutique contenant un derive d'amidine et de la procaine |
| AU49482/97A AU4948297A (en) | 1996-10-18 | 1997-10-17 | Pharmaceutical preparation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29618094.7 | 1996-10-18 | ||
| DE29618094U DE29618094U1 (de) | 1996-10-18 | 1996-10-18 | Pharmazeutisches Präparat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998017266A2 true WO1998017266A2 (fr) | 1998-04-30 |
| WO1998017266A3 WO1998017266A3 (fr) | 1998-06-25 |
Family
ID=8030722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/005724 WO1998017266A2 (fr) | 1996-10-18 | 1997-10-17 | Preparation pharmaceutique contenant un derive d'amidine et de la procaine |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0936907A2 (fr) |
| AU (1) | AU4948297A (fr) |
| DE (1) | DE29618094U1 (fr) |
| WO (1) | WO1998017266A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000030611A3 (fr) * | 1998-11-24 | 2000-08-31 | Chambord Ltd | Preparation pharmaceutique |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4309415C2 (de) * | 1993-03-19 | 1996-11-07 | Alain Jaques Bourdichon | Pharmazeutisches Präparat |
| EP0643964A3 (fr) * | 1993-08-18 | 1995-08-09 | Medipharma Sa | Utilisation d'anesthétiques locaux pour la fabrication d'un médicament pour protéger les membranes de cellules plasmatiques. |
| DE19530708C2 (de) * | 1995-08-21 | 1999-01-07 | Atarost Allg Tierarzneimittelf | Pharmazeutisches Präparat mit trypanoziden Eigenschaften |
-
1996
- 1996-10-18 DE DE29618094U patent/DE29618094U1/de not_active Expired - Lifetime
-
1997
- 1997-10-17 AU AU49482/97A patent/AU4948297A/en not_active Abandoned
- 1997-10-17 WO PCT/EP1997/005724 patent/WO1998017266A2/fr not_active Application Discontinuation
- 1997-10-17 EP EP97912195A patent/EP0936907A2/fr not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000030611A3 (fr) * | 1998-11-24 | 2000-08-31 | Chambord Ltd | Preparation pharmaceutique |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4948297A (en) | 1998-05-15 |
| DE29618094U1 (de) | 1998-02-12 |
| EP0936907A2 (fr) | 1999-08-25 |
| WO1998017266A3 (fr) | 1998-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69224080T2 (de) | Verwendung von nsaid zur behandlung von demenz | |
| DE3705151A1 (de) | Warzenmittel | |
| DE10197266T5 (de) | Verfahren zur örtlichen Betäubung und Schmerzstillung | |
| DE60106026T2 (de) | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen | |
| DE3876963T2 (de) | Tablette für Haustiere. | |
| DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
| EP1020192B1 (fr) | Composition anti-cellulitique | |
| WO1998017266A2 (fr) | Preparation pharmaceutique contenant un derive d'amidine et de la procaine | |
| DE19530708C2 (de) | Pharmazeutisches Präparat mit trypanoziden Eigenschaften | |
| EP0407634B1 (fr) | Médicament analgésique et anti-inflammatoire | |
| DE2720420A1 (de) | Wirkstoffkombination gegen sonnenerythem und diese enthaltendes arzneimittel | |
| DE69005909T2 (de) | Mischung von Vitamin A in physiologischer Dosis und verschiedenen Wirkstoffen mit therapeutischer Wirksamkeit. | |
| EP1220668B1 (fr) | Utilisation de diminazen-di-aceturate avec/ou de la pentamidine pour traiter la malaria | |
| DE69019956T2 (de) | Pharmazeutische zusammensetzungen zur behandlung von hauterkrankungen, insbesondere pyogener und atopischer dermatitis und verfahren zu deren herstellung. | |
| DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
| WO2000030611A2 (fr) | Preparation pharmaceutique | |
| DE102022124240A1 (de) | Traditionelles chinesisches Medikament und Herstellungsverfahren für selbiges | |
| DE3030314A1 (de) | Arzneimittel auf sulfonamidbasis | |
| DE2551962C3 (de) | Verwendung eines Extraktes aus verschiedenen Spezies von Helleborus | |
| EP0291751B1 (fr) | Préparation pharmaceutique constituée par un mélange | |
| DE19819703A1 (de) | Mittel zum Repellieren von Insekten und Verfahren zur Herstellung desselben | |
| AT215736B (de) | Verfahren zur Herstellung von intravenös injizierbaren Kombinationspräparaten zur Bekämpfung von Endoparasiten in Säugetieren | |
| DE19854139A1 (de) | Pharmazeutisches Präparat mit trypanoziden und blutschizontoziden Eigenschaften | |
| DE202024103115U1 (de) | Resveratrol-basierte Zusammensetzung zur Prävention von Typ-2-Diabetes | |
| DE3341122A1 (de) | Aeusserlich anzuwendendes virucides arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1997912195 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997912195 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997912195 Country of ref document: EP |